It's designed to take the place of complicated, multiple drug regimens that many people with HIV need to follow. And it's ...

HIV spreads in the human body by targeting and infecting T cells, the critical white blood cells of our immune system. PrEP works by blocking HIV from replicating inside T cells after exposure, ...

Today, advancements in medicine have rendered HIV a manageable condition that allows most individuals to enjoy a typical ...

India introduced PrEP guidelines in 2022, but access remains limited due to lack of public rollout, low awareness, and high costs. Meanwhile, HIV prevalence has declined overall but remains ...

The consolidated evidence reveals that there is considerable cross-country price variation, particularly for second-line regimens where prices increase significantly with income level highlighting ...

The award supports development of a portable test system using the firm's protein nucleic acid probes and semiconductor sensor tech.

For people living with human immunodeficiency virus (HIV), life-saving antiretroviral therapy keeps their HIV-infected immune cells from making new copies of the virus, preventing illness and ...

Scientists at Gladstone Institutes, in collaboration with a team at the San Francisco Veterans Affairs Medical Center, have developed a novel tool—named HIV-seq—for profiling the features of rare ...

Although HIV infection remains a global public health challenge, ART has transformed it from a fatal illness to a manageable lifetime condition for those who are successfully being treated.Initially, ...

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), may be able to effectively replace more complicated HIV treatment regimens used by ...

For people living with human immunodeficiency virus (HIV), life-saving antiretroviral therapy keeps their HIV-infected immune cells from making new copies of the virus, preventing illness and ...

An international research team has identified a novel HIV antibody that targets the virus at a particularly vulnerable site and overcomes previous limitations of known antibodies. This study, led by ...